Diabetes

PPARγ agonists may improve outcomes for patients with acute myeloid leukemia.

Patients treated with Bydureon BCise had an average HbA1c reduction of 1.4% after 28 weeks.

Antibiotics were previously thought to increase the incidence of certain autoimmune diseases.

Top articles of the week from The American Journal of Pharmacy Benefits.

A ketogenic state may provide benefits for patients with diabetes.

Once-weekly injection of semaglutide recommended for approval for improved glycemic control in adults with type 2 diabetes.

Officials with Novo Nordisk have announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes.

This year, the FDA is on pace to approve about 38 new medications. Here is a look at 5 of those.

Better medication adherence may not result in lower short-term medical costs for patients with diabetes.

Pharmacists are uniquely suited helping patients figure out the optimal therapies for their diabetes.

Stress, food, lack of water, and other issues impact the body's physiology, and pharmacists can counsel patients to adjust these issues to live healthier lives.

Enzymes that activate blood vessel formation crucial for wound healing.

The National Clinical Care Commission Act would better coordinate diabetes research.

Lyrica extended-release tablets treat neuropathic pain associated with diabetic peripheral neuropathy and the management of postherpetic neuralgia.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

Although there are many ways a patient can reduce the risk for diabetes or complications from diabetes, pharmacists have intimate knowledge of a patient

Patient education and understanding the relationship between hyperglycemia, peripheral vascular disease, neuropathy, and foot complications are essential to reduce the potential for foot injury, ulceration, or amputation.

One of the biggest struggles facing patients today is ensuring they have the proper medications on hand and that they are taking their medications correctly.

Sodium-glucose co-transporter-2 inhibitors are a class of antihyperglycemic agents that can be used to improve glycemic control in the treatment of type 2 diabetes.

Many patients with T2D will require insulin therapy; however, these patients are also likely to develop insulin resistance over time.

Merck has entered an agreement to develop KalVista Pharmaceuticals’ investigational DME drug.

The role of pharmacists have expanded to help patients set goals and ensure that diabetes medication regimens are streamlined.

Clinical pharmacists have proven talents when it comes to managing patients who have diabetes.